Kyowa Hakko Kirin Articles
Advantages of Tivopath over currently used kidney cancer therapies seen by thought leaders
27 March 2013
Kyowa Hakko and Astellas get new indication for Pasetocin and Sawacillin; latter applies for new Dormicum use
21 February 2013
Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data
28 January 2013
Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko
15 January 2013
Drug development deals for Kyowa Hakko/Adimab, Daiichi Sankyo/Amplimmune and Chugai/Debiopharm
8 January 2013
News briefs from Genzyme, Sagent, Orchid and Kyowa Hakko
14 November 2012
Kyowa Hakko files for additional indications for Leunase
8 October 2012
Kyowa Hakko Kirin returns rights to Busulfex to Otsuka
17 September 2012
Japan's drug majors post mixed financial results
31 July 2012
Kyowa Hakko Kirin starts Ph III trial of ARQ 197 (tivantinib) in NSCLC patients in Asia
10 August 2011
Merck Serono strengthens executive team; ProStrakan names new CEO; Sanofi Pasteur MSD gets new president
8 July 2011
Novartis wins in Apotex patent case; gout drug ACZ885 reduced risk of new attacks by up to 68% vs steroid
26 May 2011
Kyowa Hakko to buy ProStrakan for around $474 million
21 February 2011
Showing 1-19 of 19 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
